
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant is positioned to potentially become a leader in the autoimmune disease space with their first-in-class FcRn inhibitor, IMVT-1402. The company has a significant milestone payment to HanAll for the development and manufacturing of their product candidates, and their upcoming Phase 2b data for IMVT-1402 in difficult-to-treat rheumatoid arthritis (RA) presents a blockbuster opportunity. Despite the recent failure of a competitor's FcRn inhibitor, Immunovant's trial design and patient population differentiate them and may increase the likelihood of success.
Bears say
Immunovant is facing a negative outlook due to risks associated with their key products not being approved yet and potential safety concerns surrounding their cholesterol safety signal for IMVT-1402. Additionally, the impact of COVID-19 on clinical development and the competitive market for their first product launch are also potential risks. While their financial update for 3Q showed some improvement, with a narrower loss per share and lower expenses, it is still uncertain when they will start generating revenue as it is not expected until 2027.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares